Clinical Trial

Remote Ischaemic Preconditioning in Transplantation (RIPTRANS)

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2020 (before its estimated March 2022 completion). Its status may not reflect the trial's current state.
Summary
Remote ischemic preconditioning (RIPC) is a concept where remotely induced ischemia produces protection against ischemia-reperfusion injury in a remote organ. RIPC has been studied extensively in animal models and heart surgery, but it's benefit in transplantation has been studied less. The primary aim of this study is to find out whether RIPC performed in a donor in donation after brain-death (DBD) could improve delayed graft function rate of kidney transplants.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-02-24; most recent amendment 2020-03-06.
Status change: Not Yet Recruiting → Recruiting 2019-08-13
Trial Details
NCT Number NCT03855722
Lead Sponsor Helsinki University Central Hospital
Collaborators: Finska Läkaresällskapet (funding), Academy of Finland, Helsinki University Hospital Research Funds (funding)
Conditions Transplant Dysfunction
Enrollment 496 participants
Start Date 2019-03-12
Primary Completion 2022-03 (estimated)
Study Completion 2042-02 (estimated)
Updated on ClinicalTrials.gov 2020-03-10